Experiencing disease relapses after receiving a placebo in a clinical trial may change the perception of health in participants with neuromyelitis optica spectrum disorder (NMOSD) and lead to an underestimation of the disease’s impact on quality of life, a study shows. This effect — known as “response shift” —…
Clinical trials
Recent Posts
- Clinical trial data show NMOSD treatment reduces relapses
- Living with NMOSD means learning how to combat decision fatigue
- Immunosuppressive treatment may lower DN-NMOSD relapse risk
- NMOSD has a way of opening our eyes to the little luxuries in life
- Adult brain can replace key cells lost in NMOSD, study finds